




# Figure S5




**Fibroblast treated with Met5A 2.8k vs VMC 2.8k EVs**



**Fibroblast treated with Met5A 10k vs VMC 10k EVs**



**Fibroblast treated with Met5A 2.8k vs MSTO 2.8k EVs**



**Fibroblast treated with Met5A 10k vs MSTO 10k EVs**

**Figure 4: Pathway Enrichment Analysis:** Differential expression results from fibroblasts (MRC5) treated with non-malignant control (Met5A), epithelioid VMC23, and non-epithelioid (MSTO) PM-derived EVs (2.8k, 10k, 100k) were used for the analysis. The gene set enrichment analysis (GSEA) was performed using the KEGG\_2021 gene set. Ridge plots summarise GSEA results for fibroblasts treated with VMC23-derived EVs (A-B) and MSTO-derived EVs (C-D). adjusted p-value  $\leq 0.05$ .